ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

31373 results sorted by trial registration date.
  • An Educational tool targeting the symptoms of constipation among people prescribed Clozapine.

    consumers prescribed Clozapine suffer from constipation; essentially double that of the general population. Clozapine consumers are 3 times more likely to develop constipation, compared to their contemporaries prescribed other antipsychotics. Ongoing questioning and screening by mental health professionals is strongly recommended, in order to detect and treat constipation in a timely manner. In my experience as a mental health case manager, and more recently as a Clozapine coordinator, the screening, detection, and management of clozapine induced constipation is severely lacking. Non-pharmacological interventions are considered the first and most important step in managing constipation. One hour of exercise, five days a week; increased fibre and fluid intake. These can be achieved with minimal support clinically, and financially. Clozapine clinics have been seen as a place to develop health agency and providing education during clinics, with a view to have the consumers engage in their own treatment interventions for constipation would be the goal. I would aim to incorporate the peer workforce and current consumers prescribed clozapine in the development of the education aspect. This RCT will consist of a control and intervention group. The control group will receive current health practices, which include 3 monthly screening and assessment for constipation by a registered nurse and /or physician. The intervention group will receive an hour of education, targeted at improving their knowledge and understanding of constipation, and given them lifestyle interventions to manage it. All participants will complete a 2 weekly constipation self-report measure called the PAC - SYM to collect data.

  • Precision Atrial Fibrillation App to support Atrial Fibrillation Management

    Atrial fibrillation (AF) is a complex heart rhythm disease. We have shown the utility of a multi-disciplinary approach for patients with AF, but applicability in real world settings with poor health literacy and unmet social needs is unknown. We hypothesize that a precision health platform can deliver integrated care in AF successfully. Therefore, we test a precision health model of care focusing on patient empowerment and self-management by promoting critical health literacy and personalised medicine utilizing a Precision Health Platform (Precision AF App). This novel approach moves away from a resource intensive multi-disciplinary approach and emphasizes health behaviour change to achieve the comprehensive AF management.

  • A novel method using textural analysis of thermal images to predict the healing status of diabetic-related foot ulcers

  • Exercise Study for Leukemia Survivors

    Purpose of the study: The aim of this study is to investigate whether a structured physical activity program undertaken following chemotherapy can improve physical fitness and heart function in acute leukaemia patients. The results of this study will be used to guide future care for acute leukaemia patients. Who is it for? You may be eligible to join this study if you are aged 18 years and above and can exercise at the time of enrolment. Study details: Participants will undergo a series of assessments prior to the beginning of the study and again at 12 weeks later. Participants will perform three exercise bouts per week which will be supervised by the study physiotherapist or exercise physiologist. They will also be given a wearable device which is used to monitor heart rate which can then be used to prescribe exercises. These study activities will be included along with the normal care from the doctors. It is hoped that this study will help determine whether exercise can assist in increasing the physical fitness and quality of life of adults with leukaemia.

  • SNIF study: Efficacy of nasally inhaled isopropyl alcohol for nausea in the intensive care unit: A randomised clinical trial

    Nasally inhaled isopropyl alcohol (IPA) is readily available and an easy-to-administer intervention, that has been shown to reduce nausea and vomiting in patients presenting to the emergency department. The purpose of this trial is to determine the effectiveness of inhaling IPA in reducing nausea and vomiting in the self-ventilating ICU patients. It is hypothesised that nasally inhaled IPA reduces the requirement for intravenous ondansetron in critically ill patients with nausea and vomiting.

  • The effects of simulated altitude on the physiological responses of older adults to strength training.

    This study aims to determine if performing strength training in simulated altitude can cause greater improvements in muscle strength and muscle size in older adults, compared to traditional strength training at sea level conditions. The study ultimately aims to help slow the progression of muscle weakness and muscle wasting in older adults. We hypothesise that performing strength training in simulated altitude (termed hypoxia) will enhance the muscle training responses compared to training at sea level.

  • Healthy Eating in Haemodialysis Study

    Haemodialysis cleans the blood and replaces some of the function of the kidneys when they are no longer working. Patients undergoing haemodialysis have traditionally been prescribed diets low in fruits and vegetables and high in animal protein, sugar and fat to prevent malnutrition and limit dietary potassium and phosphate. Research has shown that healthy diet patterns high in fruits, vegetables, nuts and legumes, and lower in meat and processed food are associated with lower risk of death in those with early stages of kidney disease, however studies examining these outcomes for haemodialysis patients are sparse. The aim of the study is to examine the extent to which healthy diet patterns and meeting core food requirements occur in our patients requiring haemodialysis and follow up participants for up to 5 years for heart disease related events. The study will use a questionnaire to collect information on dietary intake from patients undergoing haemodialysis. Data will be examined for diet quality by food groups and assessed against healthy diet criteria.

  • Strive to Thrive: Piloting a self-management tool for stroke survivors

    Strive to Thrive was created by people with a lived experience of stroke, clinicians and researchers. It is designed to help people who have had a stroke identify what helps and hinders them at their work and create a personalised action plan to manage the impact of the stroke on their day-to-day work life. We want to see if Strive to Thrive is acceptable to a broader group of people who have had a stroke, and make further adjustments and improvements based on their feedback. If Strive to Thrive is acceptable and seen as useful, we can then do a larger study to find out if it has a positive effect on the person who has had a stroke.

  • C No More: Mobile hepatitis C testing and treatment for people on community corrections orders

    This is a pilot feasibility study to evaluate mobile rapid point-of-care hepatitis C antibody and RNA testing and treatment initiation for individuals completing community correction orders, who are at high risk of viral hepatitis but currently cannot access prison-based hepatitis screening and treatment programs. This study will evaluate the feasibility, acceptability and efficacy of point-of-care fingerstick testing for hepatitis C antibodies and hepatitis C viral load, as well as rates of direct-acting antiviral (DAA) initiation (including same day hepatitis C testing and initiation of treatment) and treatment outcomes. A mobile clinic van fitted with medical equipment and staffed by a hepatitis clinical nurse consultants and peer mentor will attend community corrections facilities to recruit individuals attending these sites. Following recruitment, study personnel will conduct hepatitis C point-of-care testing, clinical assessments from the van, and initiate DAA therapy and discuss harm reduction strategies where appropriate. The study is a prospective cohort design recruiting consecutive participants at designated community correction sites over an 18 month period. Participants will be tested for hepatitis C exposure using a point of care antibody test. For participants who test positive for hepatitis C antibodies, current hepatitis C infection will be tested using rapid POC HCV VL fingerstick testing through the mobile van service. All participants who have current hepatitis C infection will be offered DAA treatment in line with the Australian consensus statement on the management of hepatitis C. Following completion of DAA therapy, participants will be monitored for an additional 4-12 weeks and offered hepatitis C point-of-care RNA PCR testing to confirm cure. The primary outcomes of the study are the feasibility of POC hepatitis C testing amongst the study population, DAA treatment initiation, uptake of same day hepatitis C testing and treatment initiation and likelihood of hepatitis C cure.

  • Low Dose Naltrexone for the treatment of long COVID-19

    Naltrexone (NTX) is an opioid receptor antagonist commonly used to treat opioid withdrawal at a dose of 50.0-100.0 mg daily. Low dose NTX (LDN), within a specific dosage window of 1-5 mg/day as been used off-label since the mid-1980s due to improvements in chronic pain, stamina, cognition, fatigue, and inflammation for many autoimmune disorders, chronic pain syndromes, malignancies, and mental health disorders to target symptoms overlapping with long COVID. There is evidence to suggest the use of LDN will be beneficial to treat patient outcomes for those with Long COVID. A randomised dose ranging double blind placebo controlled 12-week clinical trial is proposed to determine the efficacy of LDN based on clinical symptoms and quality of life. Primary and secondary outcomes will be assessed through a series of online questionnaires to determine changes in symptom presentation (primary outcome) and through a series of validated patient reported outcome measures for quality of life.

Tags:
  • Finding clinical trials